Search
Metformin
go.drugbank.com/drugs/DB00331ApprovedInvestigational[A36559] Metformin was first approved in Canada in 1972,[A36552] and received subsequent FDA approval in the US in 1995.[L12207] … It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels.
Mixtures: XIGDUO XR TABLETS 10MG/500MG, XIGDUO XR TABLETS 10MG/1000MGCategories: metformin and acarbose, Alimentary Tract and MetabolismOrphenadrine
go.drugbank.com/drugs/DB01173ApprovedInvestigationalA muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
Mixtures: Hovid Paracetamol and Orphenadrine Citrate Tablet 450mg/35mg, Orphenadrine Citrate, Aspirin and CaffeineCategories: Metabolic Side Effects of Drugs and SubstancesMethadone
go.drugbank.com/drugs/DB00333ApprovedInvestigationalUse of OAT is also intended to lead to social stabilization by reducing crime rates, incarceration, use of illicit opioids such as [heroin] or [fentanyl], and ultimately marginalization. … ) receptor, and as an inhibitor of serotonin and norepinephrine uptake.
Products: Alphadone Syrup 10mg/ml, METADONA SOLUCIÓN ORAL 10MG/MLAzilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalLowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. … Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011.
Mixtures: EDARBI CLD® 40MG/12.5MGCategories: azilsartan medoxomil and diuretics, Angiotensin II receptor blockers (ARBs) and diureticsEvolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalEvolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface, resulting in more LDL receptors on the surface of the liver to remove LDL-C from the blood. … It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies.
Categories: Amino Acids, Peptides, and ProteinsProducts: REPATHA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 140MG/ML, Repatha Solution for Injection in Pre-filled Syringe 140mg/mL (evolocumab)Olipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145] … [L42740] ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and the abnormal accumulation of the primary ASM substrate, sphingomyelin
Categories: Enzymes and Coenzymes, Alimentary Tract and MetabolismProducts: XENPOZYME 20MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSIONYeast
go.drugbank.com/drugs/DB11017ApprovedYeast allergenic extract is used in allergenic testing.
Categories: Alimentary Tract and MetabolismProducts: BIOFLOR SACHETS 250MG, BIOFLOR CAPSULES 250MGFulvestrant
go.drugbank.com/drugs/DB00947ApprovedInvestigationalIt is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.
Categories: Antineoplastic and Immunomodulating Agents, Hormone Antagonists and Related AgentsProducts: FASLODEX SOLUTION FOR INJECTION 250MG/5 ML, FULVESTRANT-TEVA SOLUTION FOR INJECTION 250MG/5MLSarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigational[A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid … [A27265] RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsProducts: KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG, KEVZARA Solution for Injection in Pre-filled Pen 150mgDihydro-alpha-ergocryptine
go.drugbank.com/drugs/DB11274ApprovedThis structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine.[T195] Both compounds are hydrogenated ergot derivatives. … Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group.
Products: ALMIRID CRIPAR 20MG, ALMIRID CRIPAR 40MG